By Kamal Choudhury (Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and ...

Shares of Novavax Inc. NVAX tumbled 19.56% to $5.43 Thursday, on what proved to be an all-around dismal trading session for ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax, the little-known Maryland company that received a $1.6 billion deal from the federal government for its experimental coronavirus vaccine, announced encouraging results in two preliminary ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

Shares in US biotech Novavax fell more than 20% before the weekend, following remarks from health and human services ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, with the long-time vaccine critic declaring that vaccines for respiratory bugs that target a sole part of ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

The US Food and Drug Administration was supposed to make a final decision about whether or not to approve Novavax's (NVAX) ...